Text Size
70 studies found for:    c-Met

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: COMBINED PF-02341066 AND PF-00299804;   Drug: PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804
2 Not yet recruiting Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use
Condition: Alcohol Abuse
Interventions: Behavioral: cASBI+cMET;   Behavioral: cASBI
3 Recruiting A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Condition: Non-small Cell Lung Cancer
Intervention: Drug: INC280
4 Recruiting A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Conditions: Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Recurrent
Intervention:
5 Not yet recruiting 11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues
Conditions: Primary Hyperparathyroidism;   Tertiary Hyperparathyroidism
Interventions: Radiation: 11C-Methionine PET/CT scanning;   Radiation: 18F-FDG PET/CT scanning;   Radiation: SPECT-CT scanning
6 Recruiting Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: INC280
7 Recruiting A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Systemic Anaplastic Large-Cell Lymphoma;   Neoplasms;   Anaplastic Lymphoma Kinase, Human;   NSCLC
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Ketoconazole
8 Recruiting A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
Condition: Solid Tumors
Intervention: Drug: MSC2156119J
9 Recruiting c-Met Inhibitor ARQ 197 (Tivantinib) in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: tivantinib;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: diagnostic laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
10 Recruiting First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor EMD 1214063 in Subjects With Advanced Solid Tumors
Condition: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Intervention: Drug: EMD 1214063
11 Recruiting Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
Condition: Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Intervention: Drug: INC280
12 Unknown † Study of Tumor Samples From Patients With Lung Cancer
Condition: Lung Cancer
Interventions: Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
13 Active, not recruiting eMet CAR RNA T Cells Targeting Breast Cancer
Conditions: Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention: Biological: cMet RNA CAR T cells
14 Terminated First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: EMD 1204831
15 Completed A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: bevacizumab;   Drug: MetMAb
16 Active, not recruiting A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
Conditions: Cancer;   Oncology;   Tumors;   Advanced Malignancy;   Advanced Solid Tumors;   Oncology Patients
Intervention: Drug: AMG 208
17 Active, not recruiting -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small Cell Lung;   Adenocarcinoma;   Carcinoma, Squamous Cell;   Carcinoma, Large Cell
Interventions: Drug: PF-00299804;   Drug: PF-02341066
18 Completed Genetic Characterisation of High-grade Paediatric Osteosarcomas
Condition: Paediatric Osteosarcomas
Intervention:
19 Active, not recruiting
Has Results 		A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression
Condition: Breast Cancer
Intervention: Drug: Polyphenon E
20 Active, not recruiting A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Condition: Carcinoma, Renal Cell
Intervention: Drug: foretinib (formerly GSK1363089 or XL880)
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years